FibroGen Priced, Nasdaq: FGEN
Developing therapies for anemia and fibrosis; backed by Astellas and AstraZeneca
Industry: Health Care
First Day Return: +22.2%
FGEN
Developing therapies for anemia and fibrosis; backed by Astellas and AstraZeneca
| IPO Data | |
|---|---|
| IPO Date | 11/13/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $146 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Francisco, CA, United States |
| Founded | 1993 |
| Employees at IPO | 337 |
| Website www.FibroGen.com | |
IPO News for FibroGen
FibroGen (FGEN) Performance
